Synfini
Menlo Park · Founded 2023
About Synfini
Synfini provides an AI-powered drug discovery platform that supports the full chemistry workflow’from molecular design through synthesis, testing, analysis, and data management. Its suite includes SynPlan for project planning and tracking, SynDesign for generating optimized molecules with minimal data, SynRoute for AI-assisted synthesis pathway planning, SynBuild for automated compound production, and SynDB as a centralized reaction and molecular data repository. The platform enables scientists to collaborate seamlessly, customize workflows, and accelerate hit-to-lead and lead optimization stages with efficiency and precision. Synfini also engages in partnerships with biotech firms like Multispan and OΓéénix Bio to apply its integrated design-make-test-analyze system to challenging targets such as GPCRs and cancer-related enzymes.
Company Facts
- Founded: 2023
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.9M
- Last round: Series Unknown (Jul 2025)
- Website: http://www.synfini.com
- Phone: 650-283-5939
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/synfini-30155 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.